The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Bioengineered Protein Drugs-Global Market Insights and Sales Trends 2024

Bioengineered Protein Drugs-Global Market Insights and Sales Trends 2024

Publishing Date : Dec, 2023

License Type :
 

Report Code : 1858850

No of Pages : 102

Synopsis
The global Bioengineered Protein Drugs market size is expected to reach US$ 110780 million by 2029, growing at a CAGR of 4.0% from 2023 to 2029. The market is mainly driven by the significant applications of Bioengineered Protein Drugs in various end use industries. The expanding demands from the Cancer, Diabetes, Autoimmune Disorder and Infectious Disease, are propelling Bioengineered Protein Drugs market. Monoclonal Antibodies, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Therapeutic Proteins segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Bioengineered Protein Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Bioengineered Protein Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Bioengineered Protein Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Bioengineered Protein Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Bioengineered Protein Drugs covered in this report include Dr.Reddy’s, Eli Lilly, Merck, Reliance Life Sciences, Panacea Biotech, Novartis, Fresenius, Sanofi and ProBioGen, etc.
The global Bioengineered Protein Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Dr.Reddy’s
Eli Lilly
Merck
Reliance Life Sciences
Panacea Biotech
Novartis
Fresenius
Sanofi
ProBioGen
GlaxoSmithKline
Roche
Amoytop Biotech
Shanghai United Cell Biotechnology
Hualan Bio
Global Bioengineered Protein Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Bioengineered Protein Drugs market, Segment by Type:
Monoclonal Antibodies
Therapeutic Proteins
Vaccines
Global Bioengineered Protein Drugs market, by Application
Cancer
Diabetes
Autoimmune Disorder
Infectious Disease
Neurodegenerative
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Bioengineered Protein Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Bioengineered Protein Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Bioengineered Protein Drugs Market Overview
1.1 Bioengineered Protein Drugs Product Overview
1.2 Bioengineered Protein Drugs Market Segment by Type
1.2.1 Monoclonal Antibodies
1.2.2 Therapeutic Proteins
1.2.3 Vaccines
1.3 Global Bioengineered Protein Drugs Market Size by Type
1.3.1 Global Bioengineered Protein Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Bioengineered Protein Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Bioengineered Protein Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Bioengineered Protein Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Bioengineered Protein Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Bioengineered Protein Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Bioengineered Protein Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Bioengineered Protein Drugs Sales Breakdown by Type (2018-2023)
2 Global Bioengineered Protein Drugs Market Competition by Company
2.1 Global Top Players by Bioengineered Protein Drugs Sales (2018-2023)
2.2 Global Top Players by Bioengineered Protein Drugs Revenue (2018-2023)
2.3 Global Top Players by Bioengineered Protein Drugs Price (2018-2023)
2.4 Global Top Manufacturers Bioengineered Protein Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Bioengineered Protein Drugs Market Competitive Situation and Trends
2.5.1 Bioengineered Protein Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Bioengineered Protein Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Bioengineered Protein Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Bioengineered Protein Drugs Market
2.8 Key Manufacturers Bioengineered Protein Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Bioengineered Protein Drugs Status and Outlook by Region
3.1 Global Bioengineered Protein Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Bioengineered Protein Drugs Historic Market Size by Region
3.2.1 Global Bioengineered Protein Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Bioengineered Protein Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Bioengineered Protein Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Bioengineered Protein Drugs Forecasted Market Size by Region
3.3.1 Global Bioengineered Protein Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Bioengineered Protein Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Bioengineered Protein Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Bioengineered Protein Drugs by Application
4.1 Bioengineered Protein Drugs Market Segment by Application
4.1.1 Cancer
4.1.2 Diabetes
4.1.3 Autoimmune Disorder
4.1.4 Infectious Disease
4.1.5 Neurodegenerative
4.1.6 Others
4.2 Global Bioengineered Protein Drugs Market Size by Application
4.2.1 Global Bioengineered Protein Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Bioengineered Protein Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Bioengineered Protein Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Bioengineered Protein Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Bioengineered Protein Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Bioengineered Protein Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Bioengineered Protein Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Bioengineered Protein Drugs Sales Breakdown by Application (2018-2023)
5 North America Bioengineered Protein Drugs by Country
5.1 North America Bioengineered Protein Drugs Historic Market Size by Country
5.1.1 North America Bioengineered Protein Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Bioengineered Protein Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Bioengineered Protein Drugs Sales in Value by Country (2018-2023)
5.2 North America Bioengineered Protein Drugs Forecasted Market Size by Country
5.2.1 North America Bioengineered Protein Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Bioengineered Protein Drugs Sales in Value by Country (2024-2029)
6 Europe Bioengineered Protein Drugs by Country
6.1 Europe Bioengineered Protein Drugs Historic Market Size by Country
6.1.1 Europe Bioengineered Protein Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Bioengineered Protein Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Bioengineered Protein Drugs Sales in Value by Country (2018-2023)
6.2 Europe Bioengineered Protein Drugs Forecasted Market Size by Country
6.2.1 Europe Bioengineered Protein Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Bioengineered Protein Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Bioengineered Protein Drugs by Region
7.1 Asia-Pacific Bioengineered Protein Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Bioengineered Protein Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Bioengineered Protein Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Bioengineered Protein Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Bioengineered Protein Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Bioengineered Protein Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Bioengineered Protein Drugs Sales in Value by Region (2024-2029)
8 Latin America Bioengineered Protein Drugs by Country
8.1 Latin America Bioengineered Protein Drugs Historic Market Size by Country
8.1.1 Latin America Bioengineered Protein Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Bioengineered Protein Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Bioengineered Protein Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Bioengineered Protein Drugs Forecasted Market Size by Country
8.2.1 Latin America Bioengineered Protein Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Bioengineered Protein Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Bioengineered Protein Drugs by Country
9.1 Middle East and Africa Bioengineered Protein Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Bioengineered Protein Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Bioengineered Protein Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Bioengineered Protein Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Bioengineered Protein Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Bioengineered Protein Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Bioengineered Protein Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Dr.Reddy’s
10.1.1 Dr.Reddy’s Company Information
10.1.2 Dr.Reddy’s Introduction and Business Overview
10.1.3 Dr.Reddy’s Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Dr.Reddy’s Bioengineered Protein Drugs Products Offered
10.1.5 Dr.Reddy’s Recent Development
10.2 Eli Lilly
10.2.1 Eli Lilly Company Information
10.2.2 Eli Lilly Introduction and Business Overview
10.2.3 Eli Lilly Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Eli Lilly Bioengineered Protein Drugs Products Offered
10.2.5 Eli Lilly Recent Development
10.3 Merck
10.3.1 Merck Company Information
10.3.2 Merck Introduction and Business Overview
10.3.3 Merck Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Merck Bioengineered Protein Drugs Products Offered
10.3.5 Merck Recent Development
10.4 Reliance Life Sciences
10.4.1 Reliance Life Sciences Company Information
10.4.2 Reliance Life Sciences Introduction and Business Overview
10.4.3 Reliance Life Sciences Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Reliance Life Sciences Bioengineered Protein Drugs Products Offered
10.4.5 Reliance Life Sciences Recent Development
10.5 Panacea Biotech
10.5.1 Panacea Biotech Company Information
10.5.2 Panacea Biotech Introduction and Business Overview
10.5.3 Panacea Biotech Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Panacea Biotech Bioengineered Protein Drugs Products Offered
10.5.5 Panacea Biotech Recent Development
10.6 Novartis
10.6.1 Novartis Company Information
10.6.2 Novartis Introduction and Business Overview
10.6.3 Novartis Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Novartis Bioengineered Protein Drugs Products Offered
10.6.5 Novartis Recent Development
10.7 Fresenius
10.7.1 Fresenius Company Information
10.7.2 Fresenius Introduction and Business Overview
10.7.3 Fresenius Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Fresenius Bioengineered Protein Drugs Products Offered
10.7.5 Fresenius Recent Development
10.8 Sanofi
10.8.1 Sanofi Company Information
10.8.2 Sanofi Introduction and Business Overview
10.8.3 Sanofi Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Sanofi Bioengineered Protein Drugs Products Offered
10.8.5 Sanofi Recent Development
10.9 ProBioGen
10.9.1 ProBioGen Company Information
10.9.2 ProBioGen Introduction and Business Overview
10.9.3 ProBioGen Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 ProBioGen Bioengineered Protein Drugs Products Offered
10.9.5 ProBioGen Recent Development
10.10 GlaxoSmithKline
10.10.1 GlaxoSmithKline Company Information
10.10.2 GlaxoSmithKline Introduction and Business Overview
10.10.3 GlaxoSmithKline Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 GlaxoSmithKline Bioengineered Protein Drugs Products Offered
10.10.5 GlaxoSmithKline Recent Development
10.11 Roche
10.11.1 Roche Company Information
10.11.2 Roche Introduction and Business Overview
10.11.3 Roche Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Roche Bioengineered Protein Drugs Products Offered
10.11.5 Roche Recent Development
10.12 Amoytop Biotech
10.12.1 Amoytop Biotech Company Information
10.12.2 Amoytop Biotech Introduction and Business Overview
10.12.3 Amoytop Biotech Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Amoytop Biotech Bioengineered Protein Drugs Products Offered
10.12.5 Amoytop Biotech Recent Development
10.13 Shanghai United Cell Biotechnology
10.13.1 Shanghai United Cell Biotechnology Company Information
10.13.2 Shanghai United Cell Biotechnology Introduction and Business Overview
10.13.3 Shanghai United Cell Biotechnology Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Shanghai United Cell Biotechnology Bioengineered Protein Drugs Products Offered
10.13.5 Shanghai United Cell Biotechnology Recent Development
10.14 Hualan Bio
10.14.1 Hualan Bio Company Information
10.14.2 Hualan Bio Introduction and Business Overview
10.14.3 Hualan Bio Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Hualan Bio Bioengineered Protein Drugs Products Offered
10.14.5 Hualan Bio Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Bioengineered Protein Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Bioengineered Protein Drugs Industrial Chain Analysis
11.4 Bioengineered Protein Drugs Market Dynamics
11.4.1 Bioengineered Protein Drugs Industry Trends
11.4.2 Bioengineered Protein Drugs Market Drivers
11.4.3 Bioengineered Protein Drugs Market Challenges
11.4.4 Bioengineered Protein Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Bioengineered Protein Drugs Distributors
12.3 Bioengineered Protein Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’